

Additional file 8, Figure S4.



E **NIRF**





5

6

Lane1: Marker Lane2: Supernatant Lane3: Flow through Lane4: Elution by 20mM imidazole Lane5: Elution by 50mM imidazole Lane6: Elution by 250mM imidazole








Lane 1: Supernatant Lane 2: Flow through Lane 3: Elution by 20mM imidazole Lane 4: Elution by 50mM imidazole Lane 5: Elution by 250mM imidazole

SRA and RING G 2 3 4 5 6 8 9 10 11



Lane1: SRA-Supernatant Lane2: SRA-Flow through

Lane3: SRA-Elution by 20mM imidazole Lane4: SRA-Elution by 50mM imidazole

Lane5: SRA-Elution by 250mM imidazole

Lane6: Marker

Lane7: RING-Supernatant Lane8: RING-Flow through

Lane9: RING-Elution by 20mM imidazole Lane10: RING-Elution by 50mM imidazole Lane11: RING-Elution by 250mM imidazole Additional file 8, Figure S4. Proteins were purified from *E. coli* lysates overexpressing different domains of UHRF1.

A. UHRF1. B. UHRF1-R235A. C. TTD-PHD. D. TTD-PHD-R235A. E. NIRF. F. PHD. G. SRA and RING.